Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fasting Conditions
NCT ID: NCT01645449
Last Updated: 2012-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
77 participants
INTERVENTIONAL
2010-06-30
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atorvastatin Calcium Tablets, 80 mg
Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
Atorvastatin Calcium Tablets, 80 mg
Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
Lipitor 80 mg Tablets
Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
Atorvastatin Calcium Tablets, 80 mg
Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin Calcium Tablets, 80 mg
Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects' weight within normal range according to normal values for Body Mass Index (1 8.0 to 30.0 kg/m2) with minimum of 50 kg weight.
3. Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within clinically acceptable range.
4. Subjects having normal 12-lead electrocardiogram (ECG).
5. systolic blood pressure between 90 mmHg to 145 mmHg (age 18 to 45 years) or 90 mmHg to 160 mmHg (above 45 years). Diastolic blood pressure between 50 mrnHg to 90 rnmHg. Pulse rate between 45 bpm and 100 bpm.
6. Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and morphine).
7. Subjects having negative alcohol breath test.
8. Women who are of childbearing potential must be using acceptable methods of birth control for 4 weeks prior to, during and 4 weeks after the last dose of trial medication and should be informed of the potential risks associated with becoming pregnant while enrolled within a clinical research trial. Accepted forms of contraception are: i.e. implants, injectables, hormonal intrauterine device, combined oral contraceptives, sexual abstinence and vasectomised sexual partner throughout the trial. Female volunteers who are post-menopausal, hysterectomised or surgically sterile may be enrolled.
9. Subjects willing to adhere to the protocol requirements and to provide written informed consent.
Exclusion Criteria
1. Hypersensitivity to the test, or reference drug, or all other used ingredients, or related class of drugs.
2. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological,neurological or psychiatric disease or disorder.
3. Individual or farniliy case medical history of any myopathy.
4. Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month before first dosing in Period 1.
5. Medical history of muscular toxic reactions during treatment with statins of fibrates.
6. Use of any prescribed or OTC medication or herbal supplements within 14 days or within 5 times the half-life of the respective active substance (whatever is longer), before first dosing in Period 1 (excluding contraceptives on women).
7. History or presence of significant alcoholism or drug abuse in the past one year. Alcoholism is defined as consumption of more than 50g of ethanol per day (12.5 cL glass of 10° \[l0%\]\] wine = 12 g; 4 cL of aperitif, 42° \[42 %\] whiskey = 17 g; 25 cL glass of 3° \[3%\] beer = 7.5 g; 25 cL glass of 6° \[6%\] beer = 15 g.
8. History or presence of significant smoking (more than 10 cigarettes/day).
9. History or presence of asthma, urticaria or other significant allergic reactions.
10. History or presence of significant gastric andlor duodenal ulceration.
11. History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
12. History or presence of cancer.
13. Difficulty with donating blood.
14. Difficulty in swallowing solids like tablets or capsules.
15. Major illness during 3 months before first dosing in Period 1.
16. Participation in a drug research study within the past 1 month before first dosing in Period 1.
17. Donation of blood in the past 2 months before first dosing in Period 1.
18. Consumption of grapefruit juice, xanthine-containing products or alcohol for within 48 hours prior to dosing.
19. Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
20. History or presence of significant easy bruising or bleeding.
21. History or presence of significant recent trauma.
22. Pregnancy or breast-feeding (for female subjects).
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr. Reddy's Laboratories Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. med. Margarete Muller
Role: PRINCIPAL_INVESTIGATOR
Nuvisan Pharma Services GmbH & Co. KG
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nuvisan Pharma Services GmbH & Co. KG
Neu-Ulm, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-VIN-095
Identifier Type: -
Identifier Source: org_study_id